Evidence map›Paper›PMID 41131393›Full record

ArticleNature cancer2025

MEF2D-expressing cancer precursors reprogram tissue-resident macrophages to support liver tumorigenesis.

Junyu Xiang, Yuanli Ni, Jiajun Yu, Hui Sun, Zhiyun Gu, Ziyong Li, Tongwang Yang, Juan Feng, Li Su, Limei Liu and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Precancerous microenvironment: A signalling perspective.Current opinion in cell biology · 2026
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Junyu Xiang *Center for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China.
Yuanli Ni *Center for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China.
Jiajun Yu *Center for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China.
Hui SunCenter for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China.
Zhiyun GuCenter for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China.
Ziyong LiCenter for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China.
Tongwang YangCenter for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China.
Juan FengCenter for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China.
Li SuDepartment of Oncology and Hematology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.
Limei LiuCenter for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China.
Jiatao LiCenter for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China.
Jesus PrietoHepatology Program, Cima, University of Navarra, Pamplona, Spain.
Matías A ÁvilaHepatology Program, Cima, University of Navarra, Pamplona, Spain.
Juanjuan ShanCenter for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China. juanjuansh@gmail.com.ORCID http://orcid.org/0000-0002-0640-1652
Na ZhuangCenter for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China. zhuangna0618@163.com.ORCID http://orcid.org/0000-0002-3908-2360
Cheng QianCenter for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China. cqian8634@gmail.com.ORCID http://orcid.org/0000-0003-1500-9991

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82120108019National Natural Science Foundation of China (National Science Foundation of China) 91959206
6 · The paper itself

Abstract

Cancers often originate from precursor cells within an inflamed microenvironment; however, the mechanisms by which these precursors manipulate the niche to promote tumorigenesis remain unclear. By combining single-cell and spatial transcriptomic analyses of precancerous lesions in hepatocellular carcinoma, here we show that elevated myocyte enhancer factor 2D (MEF2D)-expressing cancer precursors reprogram liver-resident macrophages, Kupffer cells (KCs), to create a growth-supportive environment. MEF2D levels induce an oncogenic and secretory phenotype in these precursors by epigenetic reprogramming, which is crucial for tumor initiation in murine models and human samples. This results in a KC-rich niche through paracrine activation of neuropilin 1 (NRP1) signaling on stem-like KC subtype-2 (KC2), driving its differentiation into KC subtype-1 (KC1)-like cells. Pro-inflammatory KC1s release cytokines, particularly IL-6, to enhance an MEF2D-mediated tumor-promoting program in nearby cancer precursors. Targeting NRP1 signaling disrupts the KC2-to-KC1-like differentiation and reduces niche inflammation, thereby inhibiting liver tumorigenesis in male mice. Thus, preventing aberrant KC subtype conversion in the precancerous microenvironment is a viable strategy for early cancer prevention.

Indexed as

CarcinogenesisCarcinoma, HepatocellularKupffer CellsLiver NeoplasmsMacrophagesMEF2 Transcription FactorsNeoplastic Stem CellsAnimalsCell DifferentiationCellular ReprogrammingHumansLiverMaleMiceMice, Inbred C57BLNeuropilin-1MEF2 Transcription FactorsNeuropilin-1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.